Literature DB >> 8684382

Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

.   

Abstract

The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity. We assessed the internal consistency and the intercorrelations for the four domains and examined changes in ratings over time. We also performed an interrater reliability study of the motor assessment. We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score. There was an excellent degree of interrater reliability for the motor scores. Our limited longitudinal database indicates that the UHDRS may be useful for tracking changes in the clinical features of HD over time. The UHDRS assesses relevant clinical features of HD and appears to be appropriate for repeated administration during clinical studies.

Entities:  

Mesh:

Year:  1996        PMID: 8684382     DOI: 10.1002/mds.870110204

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  588 in total

1.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Medication Management Capacity and Its Neurocognitive Correlates in Huntington's Disease.

Authors:  Catherine A Sumida; Emily J Van Etten; Francesca V Lopez; David P Sheppard; Eva Pirogovsky-Turk; Jody Corey-Bloom; J Vincent Filoteo; Steven P Woods; Paul E Gilbert; Maureen Schmitter-Edgecombe
Journal:  Arch Clin Neuropsychol       Date:  2019-10-24       Impact factor: 2.813

3.  Comorbidities of obsessive and compulsive symptoms in Huntington's disease.

Authors:  Karen E Anderson; Carissa R Gehl; Karen S Marder; Leigh J Beglinger; Jane S Paulsen
Journal:  J Nerv Ment Dis       Date:  2010-05       Impact factor: 2.254

4.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

Review 5.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 6.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Understanding the need for assistance with survey completion in people with Huntington disease.

Authors:  Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi
Journal:  Qual Life Res       Date:  2017-12-06       Impact factor: 4.147

8.  The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease.

Authors:  Carrie B Hurelbrink; Simon J G Lewis; Roger A Barker
Journal:  J Neurol       Date:  2005-03-07       Impact factor: 4.849

Review 9.  Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss
Journal:  Neurology       Date:  2014-04-29       Impact factor: 9.910

10.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.